Securities Code: 001300 Securities Abbreviation: SanboShuo Announcement No.: 2026-021
Qingdao SanboShuo Health Technology Co., Ltd. Announcement on the Company and Its Subsidiaries Engaging in Foreign Exchange Derivative Transactions
The Company and the Board of Directors guarantee the authenticity, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or material omissions.
Qingdao SanboShuo Health Technology Co., Ltd. (hereinafter referred to as the "Company") held the Fourteenth Meeting of the Second Board of Directors on April 24, 2026, and reviewed and approved the "Proposal on the Company and Its Subsidiaries Engaging in Foreign Exchange Derivative Transactions." It is agreed that the Company and its subsidiaries will engage in foreign exchange derivative transactions with a principal amount not exceeding USD 100 million or its equivalent in RMB, using their own or self-raised funds, for the purpose of hedging. The validity period will be 12 months from the approval of the 2025 annual shareholders' meeting, and the outstanding foreign exchange derivative transactions at any point in time shall not exceed the authorized total limit.
The engagement in foreign exchange derivative transactions this time does not constitute a related party transaction. In accordance with the "Articles of Association of Qingdao SanboShuo Health Technology Co., Ltd." and relevant company regulations, the specific content of the foreign exchange derivative transactions is as follows: